secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0000886163-26-000027
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Ligand terminates TR-Beta license with Viking over alleged material breach; Viking disputes
--------------------------------------------------------------------------------

- Termination of TR-Beta Program (including VK2809 and VK0214) effective May 4, 2026.
- Ligand asserts Viking materially breached obligation to use commercially reasonable efforts.
- Viking disputes termination; Ligand intends to vigorously enforce its termination rights.
- Upon termination, licenses revert to Ligand; Viking must grant non-exclusive worldwide royalty-bearing license at low single digits royalty rate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616326000027/0000886163-26-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616326000027/lgnd-20260424.htm
  HTML page:      https://secwatch.observer/filing/0000886163-26-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer